---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009526"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T15:40:42.018530+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake

## Summary
- Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).
- Consideration includes 700,000 common shares, $440,000 cash, 10.56 Bitcoin and 300 Ethereum to Orbit Capital.
- Liora holds assets for LIGHT proton-based radiotherapy system acquired from Advanced Oncotherapy PLC.
- Orbit retains 20% of Liora after terminating original royalty agreement and Series C Preferred exchange.
- Agreement effective November 21, 2025, executed March 6, 2026 to unify multiple transaction documents.

## SEC filing metadata
- accession: 0001493152-26-009526
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315226009526/0001493152-26-009526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315226009526/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009526
- JSON: https://secwatch.observer/filing/0001493152-26-009526.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009526.txt

## Key facts
- Material Agreements
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Amended and Restated Share Exchange Agreement with Orbit Capital Inc. valued at Amends and restates the Share Exchange Agreement dated November 21, 2025 (effective 2025-11-21).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: Orbit Capital Inc.
  - Value: Amends and restates the Share Exchange Agreement dated November 21, 2025
  - Effective: 2025-11-21
  source text: On March 6, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Liora Technologies Europe Ltd, a subsidiary of the Company (“Liora”) and Orbit Capital Inc., (“Orbit”), entered into an Amended and Restated Share Exchange Agreement with an effective date of November 21, 2025 (the A&R Agreement).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315226009526/0001493152-26-009526-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.